S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
NASDAQ:BTMD

biote (BTMD) Stock Price, News & Analysis

$5.71
-0.18 (-3.06%)
(As of 04/16/2024 ET)
Today's Range
$5.68
$5.94
50-Day Range
$3.97
$6.91
52-Week Range
$3.65
$8.22
Volume
61,577 shs
Average Volume
116,580 shs
Market Capitalization
$425.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.11

biote MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
42.0% Upside
$8.11 Price Target
Short Interest
Bearish
2.64% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.68mentions of biote in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
53.85%
From $0.39 to $0.60 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.54 out of 5 stars

Medical Sector

416th out of 930 stocks

Medicinals & Botanicals Industry

3rd out of 11 stocks

BTMD stock logo

About biote Stock (NASDAQ:BTMD)

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.

BTMD Stock Price History

BTMD Stock News Headlines

Can't believe it's happening again
One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.
Can't believe it's happening again
One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.
Preview: Biote's Earnings
Birmingham manufacturer to be acquired for $8.5M
Biote price target lowered by $1 at Truist, here's why
Biote names Robert Peterson as its CFO
Biote Names Robert Peterson CFO
Biote Names Robert Peterson as Chief Financial Officer
biote Should Keep Delivering Strong Growth
BIOTE GAAP EPS of $0.24, revenue of $45.6M
Biote Reports Third Quarter 2023 Financial Results
See More Headlines
Receive BTMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for biote and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/12/2024
Today
4/16/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medicinals & botanicals
Sub-Industry
N/A
Current Symbol
NASDAQ:BTMD
Employees
194
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.11
High Stock Price Target
$9.00
Low Stock Price Target
$6.55
Potential Upside/Downside
+42.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$3.32 million
Pretax Margin
-0.07%

Debt

Sales & Book Value

Annual Sales
$185.36 million
Cash Flow
$0.47 per share
Book Value
($0.58) per share

Miscellaneous

Free Float
59,626,000
Market Cap
$425.57 million
Optionable
Not Optionable
Beta
0.87
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Marc D. Beer (Age 59)
    Executive Chairman
    Comp: $484k
  • Ms. Teresa S. Weber (Age 71)
    CEO & Director
    Comp: $3.7M
  • Ms. Mary Elizabeth Conlon (Age 43)
    VP of Business Development, General Counsel & Corporate Secretary
    Comp: $475k
  • Mr. Robert Peterson
    Chief Financial Officer
  • Mr. Joe Butler (Age 62)
    Chief Information Officer
  • Mr. James Elliott Gibbs II
    Chief People Officer
  • Mr. Richard Kevin Key (Age 53)
    Chief Digital Officer
  • Mr. Jade Beutler (Age 61)
    Head of Nutraceuticals
  • Dr. Ross W. McQuivey M.D. (Age 52)
    Chief Medical Officer & Member of Medical Advisory Board
  • Dr. Cory Rice D.O.
    Chief Clinical Advisor & Member of Medical Advisory Board

BTMD Stock Analysis - Frequently Asked Questions

Should I buy or sell biote stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for biote in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BTMD shares.
View BTMD analyst ratings
or view top-rated stocks.

What is biote's stock price target for 2024?

5 equities research analysts have issued twelve-month price targets for biote's shares. Their BTMD share price targets range from $6.55 to $9.00. On average, they predict the company's share price to reach $8.11 in the next year. This suggests a possible upside of 42.0% from the stock's current price.
View analysts price targets for BTMD
or view top-rated stocks among Wall Street analysts.

How have BTMD shares performed in 2024?

biote's stock was trading at $4.94 at the beginning of 2024. Since then, BTMD stock has increased by 15.6% and is now trading at $5.71.
View the best growth stocks for 2024 here
.

Are investors shorting biote?

biote saw a increase in short interest in March. As of March 31st, there was short interest totaling 878,200 shares, an increase of 16.4% from the March 15th total of 754,400 shares. Based on an average daily volume of 117,500 shares, the short-interest ratio is presently 7.5 days. Currently, 2.6% of the company's stock are short sold.
View biote's Short Interest
.

When is biote's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our BTMD earnings forecast
.

How were biote's earnings last quarter?

biote Corp. (NASDAQ:BTMD) issued its quarterly earnings results on Tuesday, March, 12th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.08 by $0.06. The firm had revenue of $45.70 million for the quarter, compared to the consensus estimate of $45.50 million. biote had a net margin of 1.79% and a negative trailing twelve-month return on equity of 45.10%.

What guidance has biote issued on next quarter's earnings?

biote issued an update on its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $200.0 million-$204.0 million, compared to the consensus revenue estimate of $203.2 million.

How do I buy shares of biote?

Shares of BTMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BTMD) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners